Generation of recombinant Orf virus using an enhanced green fluorescent protein reporter gene as a selectable marker by Ning, Zhangyong et al.
RESEARCH ARTICLE Open Access
Generation of recombinant Orf virus using an
enhanced green fluorescent protein reporter
gene as a selectable marker
Zhangyong Ning
1,2†, Yongzheng Peng
1,3†, Wenbo Hao
4†, Chaohui Duan
1,5, Daniel L Rock
1 and Shuhong Luo
1,4*
Abstract
Background: Reporter genes are often used as a selectable marker for generation of recombinant viruses in order
to investigate the mechanism of pathogenesis and to obtain candidate vaccine viruses. Routine selection of the
recombinant parapoxvirus is time-consuming and labor intensive. Therefore, developing a novel method for
selection is critical.
Results: In this study, we developed a rapid method to generate recombinant Orf viruses (ORFV) based on the
enhanced green fluorescent protein (EGFP) reporter gene as a selectable marker. The coding sequence of EGFP
gene was amplified from pEGFP-N1 vector and subcloned into the pZIPPY-neo/gus plasmid under the control of
the early-late vaccinia virus (VACV) VV7.5 promoter and flanked by two multiple cloning sites (MCS) to generate a
novel transfer vector pSPV-EGFP. Using the pSPV-EGFP, two recombination cassettes pSPV-113LF-EGFP-113RF and
pSPV-116LF-EGFP-116RF were constructed by cloning the flanking regions of the ORFV113 and ORFV116 and
inserted into two MCS flanking the EGFP gene. Using this novel system, two single gene deletion mutants OV-
IA82Δ113 and OV-IA82Δ116 were successfully generated.
Conclusions: This approach shortens the time needed to generate recombinant ORFVs (rORFVs). Thus, the pSPV-
EGFP vector provides a direct, fast, and convenient way to manipulate the recombinant viruses, indicating that it is
highly suited for its designed purpose.
Background
Orf virus (ORFV), the prototypic member of the Para-
poxviridae, is the cause of a papular demertitis in sheep
and goats known as contagious ecthyma [1]. ORFV has
been used in veterinary medicine as a preventive and
therapeutic immunomodulatory agent. Live or inacti-
vated ORFV preparations exhibit dose-dependent immu-
nomodulatory effects when administered to multiple
animal species including cattle, horses, cats and dogs.
Significant therapeutic efficacy of ORFV preparations in
preventing or treating stress-associated and other infec-
tious disease conditions has been well documented
[1-4]. However, ORFV functions (genes/proteins/
mechanisms of action) associated with modulation and
manipulation of host immune responses are still poorly
understood.
Previously we identified 16 novel, mostly terminally
located ORFV genes with putative virulence and host
range functions [5], hypothesizing that these proteins
perform novel but undescribed immunomodulatory
functions in the host. To investigate the role of these
genes during virus infection, one approach to studying
uncharacterized genes is to create mutations and/or
deletions of specific ORFV genes to disrupt their func-
tion. This can be achieved by using transfer vectors
designed to insert into site-specific locations of the viral
genome via homologous recombination [6]. However,
the experimental procedures to generate and isolate
rORFVs are adapted from standard protocols used in
generation of the vaccinia vi r u s .T h i sp r o t o c o li sl a b o r
intensive and time consuming [7,8].
The Green Fluorescent Protein (GFP) was discovered
by Shimomura et al as a companion protein to aequorin
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any medium, provided the original work is properly cited.[9], the famous chemiluminescent protein from
Aequorea jellyfish which exhibits bright green fluores-
cence when exposed to blue light [10,11]. In cellular
and molecular biology, the GFP gene is frequently used
as a reporter of expression [12]. Lately, the Enhanced
Green Fluorescent Protein (EGFP) was developed and
has been introduced and expressed in many bacteria
[13], yeast and other fungi [14], fish [15], plants [16],
flies [17] and mammalian cells [18] including human. In
recent years, recombinant GFP/EGFP expression
coupled with flow cytometry to produce an individual
cell-based readout with increased sensitivity has been
widely utilized to generate recombinant vaccinia viruses
to study virus tropism and a high-throughput vaccinia
virus neutralization assay [19-22].
In the present study, to shorten the time required to
generate rORFVs, we took advantage of EGFP reporter
gene as a selection marker to isolate rORFVs. The novel
transfer vector pSPV-EGFP was constructed to express
EGFP in rORFVs. Using this novel system, two single-
gene deletion mutants OV-IA82Δ113 and OV-
IA82Δ116 were successfully generated. This new
approach allowed us to generate the desired rORFVs in
less than 15 days. Compared to the neo/gusA selection,
EGFP selection provides a direct, fast and convenient
way to construct recombinant viruses, indicating the
usefulness of the pSPV-EGFP vector.
Results
Generation of rORFVs using neo/gusA selection
To generate rORFVs, the convenient and efficient meth-
ods for identifying recombinants are necessary. In recent
years, to improve the efficiency of recombinant isolation,
the combination of drug selection and identifiable color
detection provides an advantage over previous methods
in the poxvirus field [7]. To investigate the functions of
these novel genes encoded by ORFV, construction of
gene-deleted mutant viruses is a first step. In previous
studies [23-25], the pZIPPY-neo/gus vector containing
the neo/gusA cassette was initially used to construct
recombinant cassettes based on the flanking regions of
ORFV002, ORFV012, ORFV024, ORFV113, ORFV116,
ORFV120 and ORFV121. The preliminary results were
summarized in Table 1. Using this strategy, four single
gene deleted-mutant recombinants OV-IA82Δ002 [23],
OV-IA82Δ024 [24], OV-IA82Δ120 (unpublished data),
OV-IA82Δ1 2 1[ 2 5 ]w e r ef i n a l l yg e n e r a t e da n di s o l a t e d
through 17 and 20 rounds of plaque purification (each
round takes at least 4 or 5 days to pick blue plaques,
Table 1). However, OV-IA82Δ012, OV-IA82Δ113, and
OV-IA82Δ116 are still contaminated with the parent
virus after more then 20 rounds of plaque purification
(Table 1). This protocol is labor intensive and time con-
suming, requiring at least 3 or 4 months to isolate and
purify recombinants. A new strategy to generate
rORFVs is critical.
Construction of recombinant cassettes with the novel
transfer vector pSPV-EGFP
To shorten the time needed to generate rORFVs, the
novel transfer vector pSPV-EGFP (Figure 1A) was con-
structed using the EGFP reporter gene to replace the
neo/gusA cassette [7]. To compare the efficiency of pla-
que purification between pZIPPY-neo/gusA [7] and
pSPV-EGFP, two ORFV proteins, ORFV113 and
ORFV116, were used for this study. Two transfer vec-
tors, pSPV-113LF-EGFP-113RF and pSPV-116LF-EGFP-
116RF, were constructed using pSPV-EGFP. These cas-
settes encode EGFP under the control of the early-late
VV 7.5 promoter, which allows for isolation and purifi-
cation of recombinant viruses by using fluorescent sig-
nals under a fluorescent microscope. This novel
experimental strategy streamlines the procedure. The
experimental steps in this new strategy include: (i) gen-
erating the OV-IA82Δ113 and OV-IA82Δ116 after
transfection of the pSPV-113LF-EGFP-113RF and pSPV-
116LF-EGFP-116RF vectors into ovine fetal turbinate
(OFTu) cells previously inoculated with OV-IA82; (ii)
visual monitoring of infected cultures by fluorescent
microscopy to assess the level of rORFV infection; (iii)
determine the optimal time (usually 24 hours during the
second round of limited dilution) to harvest cells for
plaque assay (Figure 1B).
Generation of OV-IA82Δ113 and OV-IA82Δ116 using EGFP
selection
When the pSPV-113LF-EGFP-113RF and pSPV-116LF-
EGFP-116RF vectors were transfected into OFTu cells
that had been previously exposed to OV-IA82 with 1.0
multiplicity of infection (MOI), spots of brightly
EGFP-positive cells appeared within 6 h, and strong
fluorescent signal was observed under fluorescent
Table 1 Comparison of generating rORFVs using the
pSPV-EGFP and pZIPPY-neo/gus vectors
OV
gene
Rounds of plaque assay Time to obtain the puried
rOVs (days)
pSPV-
EGFP
pZIPPY-neo/
gus
pSPV-
EGFP
pZIPPY-neo/
gus
ORFV002 -
a 16 - 80[23]
b
ORFV012 - 20 - >100
C
ORFV024 - 19 - 95[24]
ORFV113 4 20 12 >100
C
ORFV116 5 20 14 >100
C
ORFV120 - 17 - 85
ORFV121 - 18 - 90[25]
a Not tested;
b Reference;
c After 20 rounds of plaque assay, still contaminated
with wild type virus.
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Page 2 of 11microscope after 24 h. Cytopathic effect (CPE) of
OFTU cells infected with OV-IA82Δ113 or OV-
IA82Δ116 (Figure 2A) was observed after 24 h during
the second round of limited dilution, and abundant
EGFP expression was observed in infected OFTu cells.
EGFP-positive cells in 96-well plates with dilutions
higher than 1:10, 000 were harvested for further plaque
purification. After two rounds of limited dilutions,
three different individual recombinant clones for each
protein were selected to run 2 or 3 times plaque assays
to remove parent virus contamination. Plaques with a
fluorescent signal can be identified in OFTu cells after
12 h pi, and individual green plaques were picked
under fluorescent microscope at 36 h pi (Figure 2B).
This demonstrates that EGFP selection substantially
shortens the time than conventional protocols such as
neo/gusA selection.
Identification of OV-IA82Δ113 and OV-IA82Δ116
To determine the purity of OV-IA82Δ113 and OV-
IA82Δ116, PCR was conducted using primers designed
from internal coding regions of ORFV113 and ORFV116
or EGFP (Table 2). The results demonstrated that the
EGFP gene was amplified from three different clones of
OV-IA82Δ113 (Figure 3A) and OV-IA82Δ116 (Figure
3B), but not from OV-IA82 or mock infected cells. In
(1) Infection (2) Transfection
Genomic ORFV DNA
L R
L R EGFP
113
V
DHR
(3) Isolation
GFP positive ORFV 
plaques on OFTu
pSVP-EGFP
B
EGFP V
pSP72
X H N B E 1 kb
pSPV-EGFP (3.457 kb)
pSP72
A
ORFV
Figure 1 Infection/transfection scheme for generation of recombinant ORFV. A. Construction of the recombinant transfer vector pSPV-
EGFP. A cassette of selectable markers of E.coli neo and gusA genes in pZIPPY-neo/gus vector was replace by the EGFP reporter gene amplified
from pEGFP-N1 vector (Clontech, CA) to generate the recombinant vector pSPV-EGFP. B. Generation of recombinant ORFV. OFTU Cells are
infected with OV-IA82 and transfected with the transfer vector pSPV-113LF-EGFP-113RF. The resultant virus mixture is then plated on OFTu cells
to eliminate OV-IA82 and the desired viruses were isolated. MCS: Multiple cloning sites. B: BglII; E: EcoRI; H: HindIII; N: NotI; and X: XhoI. V:
vaccinia virus (strain WR) VV early/late protomer VVp7.5. L: Up stream of ORFV113 un-transcription region; R: Down stream of ORFV113 un-
transcription region. DHR: double homologous recombination.
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Figure 2 Fluorescent microscopy showing the cytopathic effects (CPE) of OFTu cells infected with OV-IA82Δ113 and OV-IA82Δ116 by
using limited dilution (A) and plaque purification (B). A. Limited dilution showed OFTu cells infected with OV-IA82Δ113 and OV-IA82Δ116
after 24 h pi. The strong fluorescent signal was observed in OFTu cells infected with both OV-IA82Δ113 and OV-IA82Δ116. (b) and (e) show the
same fields as in (a) and (d) by bright-field microscopy. (c) and (f), overlay of (a) and (b) or (d) and (e). Cells were visualized in a Leica SP2
microscope in 63 × magnification. Bar, 10 μm. B. Plaque purification showed the plaques with strong fluorescent signal in OFTu cells infected
with OV-IA82Δ113 (a, b, c) and OV-IA82Δ116 (d, e, f) at 36 h pi during the second round of plaque purification. (b) and (e) show the same fields
as in (a) and (d) by bright-field microscopy. (c) and (f), overlay of (a) and (b) or (d) and (e). Cells were visualized in a Leica DMI4000B inverted
microscope in 10× magnification. Bar, 20 μm.
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fied from OV-IA82 infected cells only (Figure 3).
To verify ORFV113 and ORFV116 genes were success-
fully deleted from OV-IA82 via the transfer vector
pSPV-EGFP and the EGFP gene was incorporated into
the OV-IA82 genome by homologous recombination;
Southern blot analysis was performed on genomic DNA
isolated from OV-IA82, OV-IA82Δ113 and OV-
IA82Δ116. The ORFV113 probe detected the ORFV113
gene in OV-IA82 (Figure 4A lower panel, lane 1) but
not in OV-IA82Δ113 (Figure 4A lower panel, lane 2).
The ORFV001 gene is the only double copy located at
Table 2 Oligonucleotide primers and restriction enzymes
Primer Sequence Restriction enzyme*
GFPFw1 5’-AACTTAGAATTCGCCACCATGGTGAGCAAGGGCGA-3’ EcoR I
GFPRv1 5’-ATCAATGCGGCCGCTTACTTGTACAGCTCGTCCA-3’ Not I
GFPintrFw2 5’-GACGTAAACGGCCACAAGTT-3’
GFPintrRv2 5’-ACTGGGTGCTCAGGTAGTGG-3’
GFPseqFw3 5’-CGACCACTACCAGCAGAACA-3’
GFPseqRv3 5’-AAGTCGTGCTGCTTCATGTG-3’
113LFFw1 5’-AGGCCTCTAAGCTTCAGGTTCCGGCTTCAGATGCGCGT-3’ Hind III
113LFRv1 5’-ATTCGCGTCGACCACCAACACTTCCATTGTTGCGGC-3’ Sal I
113RFFw2 5’-TCTTATGCGGCCGCGAGCCGCCGATGCAGATCGAGGTA-3’ Not I
113RFRv2 5’-ATTCGCAGATCTTCGATCGCCAGTGCGCGGCGCATG-3’ Bgl II
113intrFw3 5’-CGCCGTAATATGCTTAACCGGAGC-3’
113intrRv3 5’-CGGACCGTGTTGGTCGTTGGGTCT-3’
113seqFw4 5’-TTAGCTTCCTTGTTTTTATC-3’
113seqRv4 5’-GTCCTTCGGGTCAGAGTCC-3’
116LFFw1 5’-GCCTCTACTAGTAGGAAGTGGCCTCGCCGACCACGA-3’ Spe I
116LFRv1 5’-ATTCGCGTCGACGTGGATGTCTCTAAGGTTCAATAC-3’ Sal I
116RFFw2 5’-TCTTATGCGGCCGCCTACCACTGGTACCAGCACCTCCT-3’ Not I
116RFRv2 5’-ATTCGCAGATCTGGCGCTACAGGCGTCCTGCAGGAA-3’ Bgl II
116intrFw3 5’-GAACAACACGTCAACCGATG-3’
116intrRv3 5’-AGGTGTGGGTTGACTTCCAG-3’
116seqFw4 5’-GTCGAGCAGATGTTCATGGA-3’
116seqRv4 5’-ATGCTGCACTTCCTGGAGAT-3’
001intrFw1 5’-CTCGGTGACCTGCCTGAC-3’
001intrRv1 5’-CTCGCGCACGTCGTAGAT-3’
* Restriction enzyme sites are underlined in prime sequences
A B
Figure 3 PCR detection of EGFP gene and ORFV113 or ORFV116 in OV-IA82Δ113 and OV-IA82Δ116. Genomic DNA was isolated from OV-
IA82 and OV-IA82Δ113 (A) or OV-IA82Δ116 (B). PCR was preformed to confirm the absence of ORFV113 (A) and ORFV116 (B) and the presence of
the EGFP reporter gene sequences in OV-IA82Δ113 and OV-IA82Δ116 genomes. M: molecular marker (HyperLadder I, Bioline); Lane 1: OV-IA82;
Lane 2 to 4: three different recombinants of OV-IA82Δ113 (A) and OV-IA82Δ116 (B).
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Figure 4 Characterization of mutants of OV-IA82Δ113 and OV-IA82Δ116 by Southern blotting. A.O V - I A 8 2 Δ113. Upper panel is a
schematic of OV-IA82 genome before and after removal of the 113 gene using the deletion vector, pSPV-EGFP by double homologous
recombination to generate gene-deletion mutant OV-IA82Δ113. Lower panel shows Southern blot analysis. Genomic DNA was isolated from OV-
IA82 (lane 1) and OV-IA82Δ113 (lane 2) and digested with restriction enzyme AflII or EcoRI respectively. The 113 internal probe was unable to
detect the 113 gene in the recombinant OV-IA82Δ113 genome, indicating that the 113 gene was completely removed from the 113 locus of the
genome. The 001 probe detected both end of the 001 loci in both OV-IA82 and OV-IA82Δ113 genomes. B. OV-IA82Δ116. Upper panel A is a
schematic of OV-IA82 genome before and after removal of the 116 gene using the deletion vector, pSPV-EGFP by double homologous
recombination to generate gene-deletion mutant OV-IA82Δ116. Lower panel shows the 116 gene, which was completely removed from the 116
locus of the OV-IA82 genome by Southern blot analysis. The 116 internal probe was unable to detect the 116 gene in the OV-IA82Δ116 genome.
The 001 probe detected both end of sequences in OV-IA82 (lane: 1) and three different clones of OV-IA82Δ116 (lanes: 2 to 4).
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ORFV001 probe detected the same pattern in both OV-
IA82 and OV-IA82Δ113, indicating that the deletion of
ORFV113 does not affect the left and right ends of the
viral genome. The EGFP probe detected the EGFP gene
in OV-IA82Δ113 but not in OV-IA82 (data not shown).
Similar results were obtained when the ORFV116 probe
was applied (Figure 4B). Sequencing of left and right
flanking regions of the deleted gene, which were
involved in the recombination, confirmed the integrity
of parental virus sequences in the mutant virus (data
not shown).
Deletion of ORFV113 and ORFV116 do not affect ORFV
replication in vitro
To investigate the infectivity of the gene-deleted mutant
viruses, a one-step growth curve was conducted. Repli-
cation properties of OV-IA82Δ113, OV-IA82Δ116, and
OV-IA82 were compared after infection of OFTu cells.
No significant differences in growth were detected
between the mutant and wild type viruses (P > 0.05) in
OFTu cells, indicating that ORFV113 and ORFV116 are
not essential for ORFV replication in OFTu cells (Figure
5). The data also demonstrates that expression of EGFP
in OV-IA82Δ113 and OV-IA82Δ116 does not affect
ORFV growth and replication in vitro. Also shown in
our previous report [23], the exogenous expression of
EGFP did not affect the viral phenotype and the biologi-
cal function in ORFV002 revertant virus (OV-
IA82Rv002GFP) which was constructed by using the
pSPV-EGFP system. Taken together, the pSPV-EGFP
vector could be widely used for recombination and for-
eign gene expression studies.
Discussion
We have shown that generating rORFVs is easy and
efficient using the EGFP reporter gene and is faster
than conventional neo/gusA methods. Using this novel
system, two single gene deletion mutants OV-
IA82Δ113 and OV-IA82Δ116 were successfully gener-
ated. Additional gene deletion mutants such as
ORFV001, ORFV005, ORFV012 and ORFV124 are
under way. The advantages of EGFP fluorescent selec-
tion compared to conventional strategies are as fol-
lows: (i) easy to construct recombinant cassettes using
the pSPV-EGFP; (ii) visual monitoring of infected cells
by fluorescent microscopy to assess the level of rORFV
infection; (iii) easy to determine the optimal time to
harvest cells; (iv) streamlining the procedures and
shortening the time needed to isolate and purify the
plaques (less than 15 days), compared to 3 or 4
months using neo/gusA method (Table 1); (v) picking
plaques directly under fluorescent microscope or by
fluorescence activated cell sorting (FACS) within 24 h
pi, no antibiotics and substrates needed; (vi) using the
pSPV-EGFP plus the pZIPPY-neo/gus allows to make a
double gene deletion mutants for multiple copy genes
or the same cluster of gene family. Moreover, EGFP
expression in infected cells provides a reliable, straight-
forward methodology to maintain viral stocks free
from contamination with spontaneous ORFV rever-
tants by the rapid selection marker of GFP-positive
cells. Furthermore, the growth curve demonstrate that
EGFP expression in recombinant viruses does not
affect the virus replication (Figure 5) and the luciferase
assay results of our previous reported OV-
IA82Rv002GFP [23] also showed that the EGFP
expression does not affect the virus biological func-
tions. Previous studies have shown that recombinant
vaccinia virus-mediated EGFP expression has been
used to monitor infection in vitro [19] or in vivo [26].
Our EGFP-based vector construct may represent a
practical tool to study ORFV infection and pathogen-
esis in natural hosts.
Conclusions
In this study, the pSPV-EGFP vector, which contains
two MCSs for insertion ORFV genes or foreign genes,
provides a reliable, straightforward methodology for the
advanced studies of ORFV replication, host range, as
well as foreign gene expression. Using this new
approach to generate and isolate rORFVs based on the
EGFP selection marker remarkably reduces the time for
recombinant virus isolation and purification. In addition,
EGFP localization will give the opportunity to study
host-virus interaction at the cellular level in vivo. Taken
together, the novel transfer vector pSPV-EGFP provides
an efficient and convenient way for gene deletion from
OV-IA82 genome to study the novel gene functions and
may also be used to acquire gene-deleted mutants from
other viruses.
Methods
Cells and viruses
Primary ovine fetal turbinate (OFTu) cells were kindly
provided by Dr. Howard D. Lehmkuhl (USDA) and
were maintained in minimal essential medium (MEM)
supplemented with 10% fetal bovine serum (FBS), 100
μg/ml streptomycin,100 U/ml penicillin, 50 μg/ml genta-
micin and 2 mM L-glutamine.
ORFV IA82 (OV-IA82) strain was isolated from lamb
nasal secretion during an orf outbreak at the Iowa Ram
Test station in 1982, and has been fully sequenced [5].
Low passage OV-IA82, which is fully virulent, was used
to construct deletion mutants OV-IA82Δ113 (Figure
4A) and OV-IA-82Δ116 (Figure 4B) and was used here
in all procedures involving infections with wild type
virus, PCR amplification and cloning of viral genes. The
Ning et al. BMC Veterinary Research 2011, 7:80
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Page 7 of 11virus was propagated in OFTu cells and was purified by
sucrose gradient ultra-centrifugation before storage at
-80°C for use.
Construction of pSPV-EGFP
To obtain the EGFP gene sequence, two primers were
designed, sense-primer GFPFw1 and antisense-primer
GFPRv1. An EcoR I site was added to the sense-primer
and Not I to the antisense-primer (Table 2). Thermo-
stable high fidelity DNA polymerase and dNTPs were
obtained from Invitrogen (Carlsbad, CA, USA). Poly-
merase chain reaction (PCR) was performed in 50 μl
thin-wall polypropylene tubes (Denville Scientific, NJ,
USA) using a PTC-200 DNA Engine thermal cycler
(Bio-Rad, Shelton, CA, USA) under the following condi-
tions: denaturation at 96°C for 2 min followed by 30
cycles of denaturation at 94°C for 45 s, annealing at 54°
C for 45 s, elongation at 72°C for 1 min, and a final
extension at 72°C for 7 min. PCR products were visua-
lized in 1% agarose gel with ethidium bromide staining,
cut out, and purified using a Qiagen gel extraction kit
(Qiagen, Valencia, CA, USA). The products were then
cloned into vector pZIPPY-neo/gus [7], which had been
linearized with EcoRI and NotI (New England Biolabs,
Ipswich, MA, USA) to generate the novel transfer vector
pSPV-EGFP (Figure 1A). The plasmid was propagated
in Escherichia coli strain Top10 (Invitrogen, Carlsbad,
CA, USA). DNA sequencing of the pSPV-EGFP was
done to ensure that the correct construct had been
obtained. The complete DNA sequence of the pSPV-
EGFP was deposited in GenBank under the accession
number: GU062789.
Construction of recombinant cassettes
DNA preparations and manipulations were performed
using standard methods as described by Sambrook et al.
[27] or followed instructions from manufactures. Two
recombination cassettes were constructed by PCR
amplifying ORFV113 and ORFV116 left and right flank-
ing regions from OV-IA82 genome using primers listed
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Figure 5 Replication characteristics of OV-IA82Δ113 and OV-IA82Δ1 1 6i nO F T uc e l l s . One step growth curves were performed in OFTu
cells. Statistics showed that there was no significant difference between wild type and mutant viruses (P > 0.05). Data represent the averages of
the results of three independent experiments. Error bars show standard deviations. Diamond: OV-IA82; Square: OV-IA82 Δ113; Triangle: OV-
IA82Δ116.
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Page 8 of 11in Table 2. The PCR products were cloned into the
pSPV-EGFP MCSs to generate pSPV-113LF-EGFP-
113RF and pSPV-116LF-EGFP-116RF. In addition, to
compare the efficiency between the pSVP-EGFP and
pZIPPY-neo/gus, seven recombinant cassettes were also
constructed using pZIPPY-neo/gus vector. The
ORFV002, ORFV012, ORFV024, ORFV113, ORFV116,
ORFV120 and ORFV121 left and right flanking regions
from OV-IA82 genome were amplified and cloned into
the pZIPPY-neo/gus MCSs, flanking the neomycin resis-
tance (neo)a n db-glucuronidase reporter (gus) genes
under control of the VACV VV7.5 and modified H5
promoters, respectively [7]. The resulting recombinant
vectors were named pZNG-ORFV002 [23], pZNG-
ORFV012, pZNG-ORFV024 [24], pZNG-ORFV113,
pZNG-ORFV116, pZNG-ORFV120, pZNG-ORFV121
[25]. All sub-cloning procedures were confirmed by
using restriction enzymes and DNA sequence analysis.
Generation of recombinant viruses
OV-IA82Δ113 and OV-IA82Δ116 viruses were con-
structed by infecting OFTu cells (in T25 flasks) at a
multiplicity of infection (MOI) of 1.0 with wild type
OV-IA 82 for 3 hours and subsequently transfecting the
cells with 10 μg of pSVP-113LF-EGFP-113RF and
pSVP-116LF-EGFP-116RF transfer vectors by standard
in vivo recombination protocols [28,29]. Transfections
were carried out using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions.
Viruses were harvested 48 h pi by scraping infected/
transfected OFTu cells into sterile 15 ml conical tubes.
The cell suspensions were vortexed, frozen/thawed 3
times, and then centrifuged at 1000 rpm, for 10 min at
4°C (Eppendorf Centrifuge 5810R, 15 amp version,
Hamburg, Germany). The supernatant (viruses) were
transferred into 2 ml cryogenic vials (Corning, NY,
USA) and stored at -80°C for future use.
In order to select and purify recombinant viruses, lim-
ited dilution and plaque assays were performed. 3 ×10
4
of OFTu cells per well were seeded into 96-well plates
one day before infection. On the second day, the cells
were infected with serial 10-fold dilutions of viruses
from 10
-1 to 10
-11 (900 μl 1 × MEM + 100 μlo fv i r u s ) .
The cells were examined under a fluorescent micro-
scope (Leica DMI4000B inverted microscope) 12 h after
inoculation. The cells exhibiting fluorescent signal with
dilutions higher than 1:10, 000 were collected for the
second round of limited dilution. Typically, after 24 h
pi, strong green fluorescent signal was observed in 96-
well plates. The cell suspensions were harvested and fro-
zen/thawed as above. The supernatant (viruses) was
stored at -80°C for use.
After 2 or 3 rounds of limited dilution, plaque assays
were carried out for further purification. 7 × 10
5 of
OFTu cells per well were passed into 6-well plates one
day before infection. On the next day, cells were
infected with serial dilutions of viruses from 10
-1 to 10
-
6. The viruses were allowed to absorb to the cells for 1
ha t3 7 ° C ,i n5 %C O 2 incubator. The medium was
removed and then the cells were overlaid with 3 ml of
MEM containing 5% of FBS and 0.5% low melting point
agarose (Sea Kem
® GTG
®, Lonza, Rockland, ME, USA).
Plaques with a GFP signal were visualized and picked 24
or 36 h pi. A minimum of 2 or 3 plaques were picked
for further plaque purification. The last plaque purified
recombinant viruses were expanded in 35 × 10 mm
dishes; genomic DNA was extracted using QIAamp
DNA blood kit (QIAGEN, Germany). PCR was per-
formed to screen for the wild type virus contamination
using internal primers from ORFV113 and ORFV116
coding regions (Table 2). PCR conditions were the same
a sd e s c r i b e da b o v ee x c e p tt h a tt h ea n n e a l i n gt e m p e r a -
ture was based on the Tm values of each primer. South-
ern blotting was further carried out to confirm that
double homologous recombination had occurred.
For comparison studies, OV-IAΔ002, ORFVΔ012, OV-
IA-82Δ024, OV-IA82Δ113, OV-IA82Δ116, OV-
IA82Δ120 and OV-IA82Δ121 were also constructed
using neo/gus selection following the procedures as
described above. The only difference is that those
recombinant viruses produced blue plaques (gusA activ-
ity) in the presence of X-gluc (Clontech, Palo Alto, CA,
USA). Blue plaques were picked at day 4 or day 5 pi.
Southern blots
Genomic DNA was extracted from OV-IA82, OV-
IA82Δ113 and OV-IA82Δ116 viruses, respectively. One
microgram of viral DNA was digested with AflII or
EcoRI (New England Biolabs, Inc.), electrophoresed via a
1.0% agarose gel and transferred via capillary action to a
nylon membrane (Bio-Rad, CA) using standard proto-
cols [30]. The membranes were hybridized with specific
digoxin (Roche, Mannheim, Germany) labeled probes,
which were generated specifically for the ORFV113,
ORFV116, ORFV001 and EGFP genes. The probes for
ORFV113, ORFV116, EGFP and ORFV001 were ampli-
fied by using internal primers (Table 2), same primers
applied for PCR detection as described above. Ampli-
cons were purified and labeled with digoxin followed
the manufacture’s instruction (Roche, Mannheim, Ger-
many). To determine the ends of recombinant viruses,
the same blots were stripped with N, N-dimethylforma-
mide (Sigma, St. Louis, MO, USA) at 50-60°C for 1 h,
until color had been removed completely. During the
stripping process, the solution needed to be changed
Ning et al. BMC Veterinary Research 2011, 7:80
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stripping buffer (0.2 M NaOH and 0.1% sodium dodecyl
sulfate) for 30 min at 37°C, and re-hybridized with a
specific digoxin labeled probe that were generated
toward the ORFV001 gene cassette. The NBT/BCIP
Detection kit (Roche, Mannheim, Germany) for nonra-
dioactive color development was used for hybridization
analysis of Southern blots according to the manufac-
ture’s instructions.
Sequencing analysis
To determine homologous recombination, three plaques,
which were confirmed by PCR detection using ORFV113
and ORFV116 internal primers (113intrFw3 and
113intrRv3 or 116intrFw3 and 116intrRv3, table 2) were
applied for sequencing analysis. Two pairs of primers
(Table 2), 113seqFw4 and GFPseqRv3; GFPseqFw3 and
113seqRv4 or 116seqFw4 and GFPseqRv3; GFPFw3 and
116seqRv4, were utilized to amplify the regions involved
in recombination. PCR conditions were the same as
described above except that the annealing temperature
was employed based on the Tm values of each primer.
The PCR products were cloned into pCR2.1 TA cloning
plasmid (Invitrogen, CA) for sequencing analysis using
an Applied Biosystems PRISM 3730 automated DNA
sequencer (Applied Biosystems, Foster City, CA, USA).
Virus expansion, titration, and growth curve
Based on the Southern blot and sequence analysis, one
clone of OV-IA82Δ113 and OV-IA82Δ116 were used
for expansion. Confluent monolayers of OFTu cells in
four T150 cm
2 flasks were infected at MOI of 1. The
viruses were harvested when all cells were rounded but
still attached (about 3 or 4 days pi). The cell suspen-
sions were prepared as above. The supernatants were
dispensed into 2 ml cryogenic vials (1 ml/vial) and
stored at -80°C for future use.
96-well plates of 90% confluent monolayers OFTu
cells were prepared as above. Rows of cells were infected
with serial 10-fold dilutions of wild type and mutant
viruses of 10
-1 to 10
-9, with one row for control (no
virus). One column was used for one dilution. CPE was
read at 2 d pi, and the final read was carried out at 7 d
pi. The median tissue culture infected dose (TCID50)
per ml was calculated using a spreadsheet.
One step growth curves were conducted as our per-
vious reports [23-25]. OFTu cells were prepared in 35 ×
10 mm dishes (7 × 10
5 cells/dish) one day before the
experiment. The cells were counted on the second day
and were infected at a MOI of 10 with wild type and
mutant virus. Virus was harvested at 0, 6, 12, 24, 36, 48
h pi and titrated. The growth curves were plotted as
titer (log10 TCID50/ml) versus time course (h) pi. Data
are presented as the mean ± standard deviation from
three independent experiments. P values were deter-
mined by using the unpaired two-tailed Student’st - t e s t .
Statistical significance was set at the 95% confidence
level.
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